143 related articles for article (PubMed ID: 27813227)
1. MiR-34a modulates ErbB2 in breast cancer.
Wang Y; Zhang X; Chao Z; Kung HF; Lin MC; Dress A; Wardle F; Jiang BH; Lai L
Cell Biol Int; 2017 Jan; 41(1):93-101. PubMed ID: 27813227
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.
Yang S; Li Y; Gao J; Zhang T; Li S; Luo A; Chen H; Ding F; Wang X; Liu Z
Oncogene; 2013 Sep; 32(36):4294-303. PubMed ID: 23001043
[TBL] [Abstract][Full Text] [Related]
3. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
4. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
5. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
[TBL] [Abstract][Full Text] [Related]
6. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
7. ErbB2 down-regulates microRNA-205 in breast cancer.
Adachi R; Horiuchi S; Sakurazawa Y; Hasegawa T; Sato K; Sakamaki T
Biochem Biophys Res Commun; 2011 Aug; 411(4):804-8. PubMed ID: 21787752
[TBL] [Abstract][Full Text] [Related]
8. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
10. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.
He XH; Zhu W; Yuan P; Jiang S; Li D; Zhang HW; Liu MF
Oncogene; 2016 Nov; 35(46):6015-6025. PubMed ID: 27065318
[TBL] [Abstract][Full Text] [Related]
11. The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer.
Xiao X; Huang X; Ye F; Chen B; Song C; Wen J; Zhang Z; Zheng G; Tang H; Xie X
Sci Rep; 2016 Feb; 6():21735. PubMed ID: 26902416
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.
Lu M; Wang T; He M; Cheng W; Yan T; Huang Z; Zhang L; Zhang H; Zhu W; Zhu Y; Liu P
Oncotarget; 2017 Apr; 8(14):23008-23019. PubMed ID: 28160563
[TBL] [Abstract][Full Text] [Related]
13. MiR-199b-5p targets HER2 in breast cancer cells.
Fang C; Zhao Y; Guo B
J Cell Biochem; 2013 Jul; 114(7):1457-63. PubMed ID: 23296799
[TBL] [Abstract][Full Text] [Related]
14. miR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer.
Hu JY; Yi W; Wei X; Zhang MY; Xu R; Zeng LS; Huang ZJ; Chen JS
Biomed Pharmacother; 2016 Apr; 79():247-53. PubMed ID: 27044835
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells.
Pang RT; Leung CO; Ye TM; Liu W; Chiu PC; Lam KK; Lee KF; Yeung WS
Carcinogenesis; 2010 Jun; 31(6):1037-44. PubMed ID: 20351093
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA signature for HER2-positive breast and gastric cancer.
Kang HS; Jang SG; Kwon SY; Park YS; Green JE; Kim HK; Ro J
Anticancer Res; 2014 Jul; 34(7):3807-10. PubMed ID: 24982406
[TBL] [Abstract][Full Text] [Related]
17. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
Kong LM; Liao CG; Zhang Y; Xu J; Li Y; Huang W; Zhang Y; Bian H; Chen ZN
Cancer Res; 2014 Jul; 74(14):3764-78. PubMed ID: 24906624
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
19. miRNA-205 affects infiltration and metastasis of breast cancer.
Wang Z; Liao H; Deng Z; Yang P; Du N; Zhanng Y; Ren H
Biochem Biophys Res Commun; 2013 Nov; 441(1):139-43. PubMed ID: 24129185
[TBL] [Abstract][Full Text] [Related]
20. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.
Ferracin M; Bassi C; Pedriali M; Pagotto S; D'Abundo L; Zagatti B; Corrà F; Musa G; Callegari E; Lupini L; Volpato S; Querzoli P; Negrini M
Mol Cancer; 2013 Oct; 12(1):130. PubMed ID: 24165569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
